MCID: HST010
MIFTS: 54

Histiocytosis

Categories: Respiratory diseases, Bone diseases, Blood diseases, Rare diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis 12 52 42 14 69
Chronic Multifocal Langerhans Cell Histiocytosis 56
Multifocal Eosinophilic Granuloma 56
Hand Schuller Christian Disease 12
Hand-Schüller-Christian Disease 56
Histiocytosis, Langerhans-Cell 69
Chronic Histiocytosis X 12
Histiocytic Syndrome 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3405
MeSH 42 D015614
NCIt 47 C3106
Orphanet 56 ORPHA99873
ICD10 via Orphanet 34 C96.5
UMLS 69 C0019618

Summaries for Histiocytosis

Disease Ontology : 12 A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as chronic multifocal langerhans cell histiocytosis, is related to histiocytosis-lymphadenopathy plus syndrome and benign cephalic histiocytosis, and has symptoms including hepatomegaly, proptosis and lymphadenopathy. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and lung, and related phenotypes are cellular and hematopoietic system

Wikipedia : 72 In medicine, histiocytosis refers to an excessive number of histiocytes, (tissue macrophages), and is... more...

Related Diseases for Histiocytosis

Diseases in the Histiocytosis family:

Malignant Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
id Related Disease Score Top Affiliating Genes
1 histiocytosis-lymphadenopathy plus syndrome 12.3
2 benign cephalic histiocytosis 12.2
3 malignant histiocytosis 12.2
4 indeterminate cell histiocytosis 12.1
5 histiocytosis, progressive mucinous 12.1
6 progressive nodular histiocytosis 12.1
7 generalized eruptive histiocytosis 12.1
8 letterer-siwe disease 12.1
9 adult pulmonary langerhans cell histiocytosis 12.0
10 non-langerhans-cell histiocytosis 12.0
11 alk+ histiocytosis 11.9
12 sea-blue histiocyte disease 11.8
13 erdheim-chester disease 11.8
14 hashimoto-pritzker syndrome 11.7
15 eosinophilic granuloma 11.6
16 rosai-dorfman disease 11.4
17 juvenile xanthogranuloma 11.4
18 gaucher's disease 11.2
19 niemann-pick disease 11.2
20 langerhans cell sarcoma 11.2
21 hemophagocytic lymphohistiocytosis 11.0
22 papular xanthoma 11.0
23 interstitial lung disease 11.0
24 dendritic cell tumor 11.0
25 reticulohistiocytic granuloma 10.9
26 primary cutaneous anaplastic large cell lymphoma 10.7
27 dentin dysplasia, type i, with microdontia and misshapen teeth 10.7
28 dysosteosclerosis 10.7
29 infantile myofibromatosis 10.7
30 rectum leiomyoma 10.6 CD1A CD207
31 juvenile nasopharyngeal angiofibroma 10.5 BRAF S100B
32 allergic encephalomyelitis 10.5 CD1A CD207 FSCN1
33 localized pulmonary fibrosis 10.4 PTPRC S100B
34 central nervous system germinoma 10.4 CD163 CD207
35 malignant giant cell tumor of the tendon sheath 10.4 PTPRC SERPINA3
36 gum cancer 10.3 ITGAX PTPRC
37 lymphoma 10.3
38 adult central nervous system germinoma 10.3 CD163 PTPRC
39 xanthoma disseminatum 10.3
40 teeth hard tissue disease 10.2 CD163 PTPRC
41 esophageal adenosquamous carcinoma 10.2 CD163 CD207 PTPRC
42 leukemia 10.1
43 parovarian cyst 10.1 BRAF SERPINA3
44 thyroiditis 10.1
45 diabetes insipidus 10.1
46 small intestine neuroendocrine neoplasm 10.0 CD163 FSCN1 S100B
47 leg dermatosis 10.0 CD163 CSF1R SERPINA3
48 sarcoma 9.9
49 acromegaly 9.9 CD163 SERPINA3
50 b-cell lymphomas 9.9

Graphical network of the top 20 diseases related to Histiocytosis:



Diseases related to Histiocytosis

Symptoms & Phenotypes for Histiocytosis

Human phenotypes related to Histiocytosis:

56 32 (show all 7)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0002240
2 proptosis 56 32 hallmark (90%) Very frequent (99-80%) HP:0000520
3 lymphadenopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0002716
4 diabetes insipidus 56 32 hallmark (90%) Very frequent (99-80%) HP:0000873
5 pulmonary infiltrates 56 32 occasional (7.5%) Occasional (29-5%) HP:0002113
6 osteolysis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002797
7 papule 56 32 occasional (7.5%) Occasional (29-5%) HP:0200034

MGI Mouse Phenotypes related to Histiocytosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 BRAF CD163 CSF1R CSF2 FSCN1 IL1RN
2 hematopoietic system MP:0005397 9.73 CSF1R CSF2 IL1RN ITGAX PTPRC SLC29A3
3 immune system MP:0005387 9.44 BRAF CD101 CD163 CD207 CSF1R CSF2

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754 657311
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
13
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
14
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
15
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
16
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
17
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
18
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
19
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
20
Asparaginase Approved Phase 3 9015-68-3
21
Pegaspargase Approved, Investigational Phase 3 130167-69-0
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
24
Butyric Acid Experimental Phase 3,Phase 2 107-92-6 264
25
Doxil Approved June 1999 Phase 3,Phase 2 31703
26
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
27 Alkylating Agents Phase 2, Phase 3, Phase 1
28 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
31 Antiemetics Phase 3,Phase 2,Phase 1
32 Antifungal Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
35 Antilymphocyte Serum Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 3,Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 3,Phase 2,Phase 1
42 BB 1101 Phase 3,Phase 2
43 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
44 Cortisol succinate Phase 3,Phase 2
45 Cyclosporins Phase 3,Phase 2,Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
48 Etoposide phosphate Phase 3,Phase 2
49 Folic Acid Antagonists Phase 3,Phase 2
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 123)

id Name Status NCT ID Phase Drugs
1 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Unknown status NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
2 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
3 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
4 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
5 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
6 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
7 Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
8 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
9 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Recruiting NCT02862054 Phase 2, Phase 3
10 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
11 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
12 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
13 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Active, not recruiting NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
14 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
15 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
16 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Not yet recruiting NCT03312751 Phase 3 Emapalumab
17 A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis Unknown status NCT01395004 Phase 2 GSK2110183
18 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
19 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
20 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
21 Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL Completed NCT00048373 Phase 2 Etanercept
22 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
23 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Completed NCT00145626 Phase 2 Chemotherapy and antibodies
24 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
25 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
26 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
27 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
28 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
29 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
30 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
31 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Recruiting NCT02425904 Phase 2 Clofarabine
32 Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis Recruiting NCT02389400 Phase 2 methotrexate
33 Denosumab for the Treatment of Adult LCH Recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
34 A Study of Lenalidomide for Adult Histiocyte Disorders Recruiting NCT02523040 Phase 2 Lenalidomide
35 Single-agent Cobimetinib for Adults With Histiocytic Disorders Recruiting NCT02649972 Phase 2 Cobimetinib
36 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
37 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
38 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
39 Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
40 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
41 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
42 Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations Recruiting NCT03213691 Phase 2 Selumetinib
43 Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
44 CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Recruiting NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
45 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
46 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
47 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
48 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
49 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
50 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

39
Bone, T Cells, Lung, Thyroid, Bone Marrow, Skin, Liver

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 1564)
id Title Authors Year
1
Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report. ( 28942734 )
2017
2
Langerhans Cell Histiocytosis With Clinical and Histologic Features of Hidradenitis Suppurativa: Brief Report and Review. ( 28937439 )
2017
3
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. ( 28512190 )
2017
4
Usual and Unusual Manifestations of Familial Hemophagocytic Lymphohistiocytosis and Langerhans Cell Histiocytosis. ( 27894453 )
2017
5
Dermoscopy of Langerhans cell histiocytosis. ( 28087041 )
2017
6
Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. ( 28889238 )
2017
7
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
8
Molluscum Contagiosum-Like Presentation of Langerhans Cell Histiocytosis: A Case and Review. ( 28730670 )
2017
9
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease. ( 28182116 )
2017
10
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. ( 28944988 )
2017
11
Tick bite mimicking indeterminate cell histiocytosis. ( 28940363 )
2017
12
CD207(+)CD1a(+) cells circulate in pediatric patients with active Langerhans cell histiocytosis. ( 28847997 )
2017
13
Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. ( 28302693 )
2017
14
Langerhans cell histiocytosis (eosinophilic granuloma) of the skull mimicking nummular headache. Report of two cases. ( 28490189 )
2017
15
Two cases of benign fibrous histiocytomas (dermatofibromas) associated with Langerhans cell histiocytosis. ( 28941307 )
2017
16
Indeterminate cell histiocytosis: a case series and review of the literature. ( 28943499 )
2017
17
Langerhans Cell Histiocytosis Mimicking Periapical Pathology in a 39-Year-Old Man. ( 28864216 )
2017
18
Langerhans cell histiocytosis of the thyroid complicated by papillary thyroid carcinoma: A case report and brief literature review. ( 28858125 )
2017
19
Langerhans Cell Histiocytosis Presenting as Chronic Otitis Externa. ( 28045847 )
2017
20
Langerhans cell histiocytosis followed by folliculotropic mycosis fungoides. ( 28670259 )
2017
21
Laryngeal Rosai-Dorfman Disease (Sinus Histiocytosis with Massive Lymphadenopathy): A Retrospective Study of 5 Cases. ( 28770226 )
2017
22
Atlanto-axial langerhans cell histiocytosis in a child presented as torticollis. ( 28868307 )
2017
23
Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis. ( 28072848 )
2017
24
Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. ( 28220299 )
2017
25
Indeterminate cell histiocytosis: A case treated with ultraviolet b narrow band phototherapy (NB UVB). ( 28661557 )
2017
26
Generalized Indeterminate Cell Histiocytosis Presenting as Eroded Papules and Crusts. ( 28633156 )
2017
27
Indeterminate Cell Histiocytosis in Children: A Case Report. ( 28610659 )
2017
28
Differentiating Intralymphatic Histiocytosis, Intravascular Histiocytosis, and Subtypes of Reactive Angioendotheliomatosis: Review of Clinical and Histologic Features of All Cases Reported to Date. ( 28027079 )
2017
29
Congenital Self Healing Langerhans Cell Histiocytosis. ( 28929464 )
2017
30
ERG1 Immunohistochemistry: Relevance for Lymph Node Histiocytosis. ( 28877073 )
2017
31
A Case with Juvenile Xanthogranuloma and Progressive Nodular Histiocytosis Overlap. ( 28297144 )
2017
32
Langerhans' cell histiocytosis with neurological injuries diagnosed from a single cutaneous lesion. ( 28954107 )
2017
33
Langerhans cell histiocytosis in an adult female presenting with widespread confluent crusted papules and review of adult cases confined to skin. ( 28880370 )
2017
34
'Bizarre' rash: adult-onset cutaneous Langerhans cell histiocytosis. ( 28077484 )
2017
35
How I manage pulmonary Langerhans cell histiocytosis. ( 28877978 )
2017
36
Targeting BRAK, MEK, mTOR, and now AKT in histiocytosis: The ongoing revolution of therapies in orphan diseases. ( 28066975 )
2017
37
Demodicosis in two patients with a previous history of Langerhans cell histiocytosis. ( 28940244 )
2017
38
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. ( 28084334 )
2017
39
Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. ( 28554492 )
2017
40
Langerhans cell histiocytosis limited to the female genital tract: A review of literature with three additional cases. ( 28932806 )
2017
41
New classification of histiocytosis. ( 28919209 )
2017
42
Cutaneous Indeterminate Cell Histiocytosis of Donor Origin After Allogeneic Hematopoietic Stem-Cell Transplantation. ( 28825606 )
2017
43
Griscelli syndrome subtype 2 with hemophagocytic lympho-histiocytosis: A case report and review of literature. ( 28357189 )
2017
44
Cholesteatoma as a complication of Langerhans Cell Histiocytosis of the temporal bone: A nationwide cross-sectional analysis. ( 28802389 )
2017
45
A Case of Pulmonary Langerhans Cell Sarcoma Simultaneously Diagnosed with Cutaneous Langerhans Cell Histiocytosis Studied by Whole-Exome Sequencing. ( 28614815 )
2017
46
Novel Clinical Observations on Benign Cephalic Histiocytosis in a Large Series. ( 28466548 )
2017
47
Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. ( 28521873 )
2017
48
Clinical course of the bony lesion of single-system single-site Langerhans cell histiocytosis - Is appropriate follow-up sufficient treatment? ( 28927957 )
2017
49
Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. ( 27040279 )
2016
50
A rare case of extensive cranial Langerhans cell histiocytosis, synchronously presenting as otitis externa and giant cell arteritis. ( 27908938 )
2016

Variations for Histiocytosis

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Pathways for Histiocytosis

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 BRAF CD101 CD163 CD1A CD207 CSF1R

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 face development GO:0060324 9.32 BRAF MAP2K1
2 monocyte differentiation GO:0030224 9.26 CSF1R CSF2
3 positive regulation of podosome assembly GO:0071803 9.16 CSF2 FSCN1
4 inflammatory response GO:0006954 9.1 CD163 CSF1R IL1RN SERPINA3 STAB1 TNFRSF8
5 regulation of axon regeneration GO:0048679 8.96 BRAF MAP2K1

Sources for Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....